司太立：关于以自有资金方式对全资子公司增资的公告

Core Viewpoint - The company aims to enhance the financial strength and competitiveness of its subsidiary, Shanghai Sitai Pharmaceutical Co., Ltd., through a capital increase of 60 million RMB, facilitating its transition from raw materials to formulations [2] Group 1: Capital Increase - Zhejiang Sitai Pharmaceutical Co., Ltd. plans to inject 60 million RMB into Shanghai Sitai to support its operations and sustainable development [2] - Following the capital increase, the registered capital of Shanghai Sitai will rise from 50 million RMB to 56 million RMB [2] - Shanghai Sitai will remain a wholly-owned subsidiary of the company after the capital increase [2]